Common use of INCORPORATION OF INFORMATION BY REFERENCE Clause in Contracts

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; • our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, filed with the SEC on May 7, 2020 and August 6, 2020, respectively; • our Current Reports on Form 8-K filed with the SEC on January 21, 2020, January 22, 2020, February 6, 2020, April 16, 2020, May 26, 2020, June 3, 2020, and June 11, 2020; • our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2020 (but only with respect to information required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2019); • the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on July 8, 2015 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness of the registration statement. We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). Written or oral requests for copies should be directed to Sierra Oncology, Inc., 0000 – 000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxx X0X 0X0, and our telephone number is (000) 000-0000. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with the SECit, which means that we can disclose important information to you by referring you to those other documents. The information incorporated which we incorporate by reference is an important part of this prospectus, and certain information that we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below below, and any future filings we make with the SEC under Section 13(a), 13(c), 14, 14 or 15(d) of the Securities Exchange Act prior to the termination of any offering of securities made by this prospectus1934, as amended: • our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3February 28, 2020; • our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, filed with the SEC on May 78, 2020 and August 610, 2020, respectively; • our Current Reports on Form 8-K K, filed with the SEC on January 2115, 2020, January 22, 2020, February 6, 2020, April June 16, 2020, May June 26, 2020, June 3July 14, 2020, July 24, 2020, July 31, 2020, August 28, 2020 and June 11August 31, 2020; and • the description of our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2020 (but only with respect common stock contained in Exhibit 4.2 to information required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2019); • the description of our common stock contained in our registration statement , filed on Form 8-A filed with the SEC on July 8February 28, 2015 under Section 12(b) of the Exchange Act2020, including any amendment or report reports filed for the purpose of updating such description, including Exhibit 4.5 to . You may access our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K for and amendments to any of these reports, free of charge on the fiscal year ended December 31SEC’s website. Information contained on, 2019or that can be accessed through, filed with the SEC on March 3our website is not part of this prospectus. In addition, 2020; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness of the registration statement. We will furnish without charge to you, on written or oral request, a copy of any or all of such the documents that has been incorporated herein by reference (reference, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates)those documents. Written or oral You should direct any requests for copies should be directed documents to Sierra OncologyCorporate Secretary, Acorda Therapeutics, Inc., 0000 – 000 Xxx Xxxx Xxxxxxx XxxxxxXxxxx Xxxx, XxxxxxxxxXxxxxxx, Xxxxxxx XxxxxxxxXxx Xxxx 00000, Xxxxxx X0X 0X0, and our telephone number is or call (000) 000-0000. See We are responsible for the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained reference in this prospectus, any accompanying prospectus supplement and in any related free-writing prospectus we prepare or authorize. We have not authorized anyone to give you any document other information, and we take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in or incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except in this prospectus is accurate as so modified or superseded, constitute a part of the date on the front of this prospectus.prospectus or incorporated document only, as the case may be. Our business, financial condition, results of operations and prospects may have changed since that date. Up to $15,250,000 COMMON STOCK PROSPECTUS SUPPLEMENT X.X. Xxxxxxxxxx & Co.

INCORPORATION OF INFORMATION BY REFERENCE. We file annual and special reports and other information with the SEC. These filings contain important information which does not appear in this prospectus. The SEC allows us to “incorporate by reference” information that we file with the SECinto this prospectus, which means that we can disclose important information to you by referring you to those other documentsdocuments which we have filed or will file with the SEC. The information incorporated We are incorporating by reference is an important part of in this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference prospectus the documents listed below and all amendments or supplements we may file to such documents, as well as any future filings we may make with the SEC on Form 20-F under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to before the termination time that all of any offering of the securities made offered by this prospectusprospectus have been sold or de-registered: • the description of our Ordinary Shares contained in our Registration Statement on Form 20-F filed with the SEC on December 26, 2012; • our Annual Report on Form 1020-K F for the fiscal year ended December 31, 20192020, filed with the SEC on March 318, 20202021; and • our Quarterly Reports reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020, filed with the SEC on May 7, 2020 and August 6, 2020, respectively; • our Current Reports on Form 8-K filed with the SEC on January March 22, 2021, March 25, 2021, April 9, 2021, May 20, 2021, May 21, 20202021, January 22May 24, 2020, February 6, 2020, April 16, 20202021, May 26, 20202021 (two filings), May 27, 2021, June 37, 20202021, June 9, 2021, June 10, 2021, June 17, 2021, June 21, 2021, June 28, 2021, July 13, 2021, July 19, 2021, July 20, 2021, July 22, 2021, and June 11July 26, 2020; • our Definitive Proxy Statement 2021 (in each case only to the extent provided in such Form 6-K). In addition, all subsequent annual reports on Schedule 14AForm 20-F filed prior to the termination of this offering, filed with and any reports on Form 6-K subsequently submitted to the SEC on April 24, 2020 (but only with respect to information required or portions thereof that we specifically identify in such forms as being incorporated by Part III of our Annual Report on Form 10-K for reference into the year ended December 31, 2019); • the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on July 8, 2015 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is forms a part, shall be considered to be incorporated into this prospectus by reference and prior to shall be considered a part of this prospectus from the effectiveness date of filing or submission of such documents. Certain statements in and portions of this prospectus update and replace information in the registration statementabove-listed documents incorporated by reference. Likewise, statements in or portions of a future document incorporated by reference in this prospectus may update and replace statements in and portions of this prospectus or the above-listed documents. We will furnish provide you without charge to youcharge, on upon your written or oral request, a copy of any or all of such the documents that has been incorporated herein by reference (in this prospectus, other than exhibits to such documents unless such exhibits which are not specifically incorporated by reference into the documents that this prospectus incorporates)such documents. Written Please direct your written or oral telephone requests for copies should be directed to Sierra OncologyRedHill Biopharma Ltd., Inc., 0000 – 000 Xxxx Xxxxxxx 00 Xx'xxxx'x Xxxxxx, XxxxxxxxxXxx Xxxx 0000000, Xxxxxxx XxxxxxxxIsrael, Xxxxxx X0X 0X0Attn: Xxxx Xxx-Xxxxx, and our telephone number is number: +000 (0000) 000-0000. See the section You may also obtain information about us by visiting our website at xxx.xxxxxxxxxx.xxx. Information contained in our website is included as an inactive textual reference only and is not part of this prospectus entitled “Where You Can Find More Information” for prospectus. The SEC maintains an Internet site, xxxx://xxx.xxx.xxx, that contains reports, proxy and information concerning how to obtain copies of materials statements, and other information regarding issuers that we file electronically with the SEC. Any statement contained in this prospectusPROSPECTUS $200,000,000 of American Depositary Shares representing Ordinary Shares, or in a documentOrdinary Shares, all or a portion of which is incorporated Warrants to Purchase American Depositary Shares, Subscription Rights and/or Units Offered by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.Company

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with the SECit, which means that we can disclose important information to you by referring you to those other documents. The information incorporated which we incorporate by reference is an important part of this prospectus supplement and the accompanying prospectus, and certain information that we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the following documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: (File No. 001-31938): • our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3February 28, 2020; • our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and June September 30, 2020, filed with the SEC on May 8, 2020, August 7, 2020 and August November 6, 2020, ; respectively; and • our Current Reports on Form 8-K K, filed with the SEC on January 15, 2020, June 16, 2020, June 26, 2020, July 14, 2020, July 24, 2020, July 31, 2020, August 28, 2020, August 31, 2020, October 5, 2020, October 19, 2020, December 1, 2020, December 21, 2020, January 22, 2020, February 6, 2020, April 16, 2020, May 26, 2020, June 3, 2020, and June 11, 2020; • our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24December 31, 2020 (and January 13, 2021. In addition, all reports and other documents that we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, but only with respect excluding any information furnished to, rather than filed with, the SEC, will be deemed to information required be incorporated by Part III reference into this prospectus supplement and the accompanying prospectus and deemed to be part of this prospectus supplement and the accompanying prospectus from the time of the filing of such reports and documents. You may access our Annual Report on Form 10-K for the year ended December 31K, 2019); • the description of our common stock contained in our registration statement Quarterly Reports on Form 10-Q, Current Reports on Form 8-A filed with K and amendments to any of these reports, free of charge on the SEC on July 8SEC’s website. Information contained on, 2015 under Section 12(b) or that can be accessed through, our website is not part of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a partsupplement and the accompanying prospectus. In addition, and prior to the effectiveness of the registration statement. We we will furnish without charge to you, on written or oral request, a copy of any or all of such the documents that has been incorporated herein by reference (reference, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates)those documents. Written or oral You should direct any requests for copies should be directed documents to Sierra OncologyCorporate Secretary, Acorda Therapeutics, Inc., 0000 – 000 Xxx Xxxx Xxxxxxx XxxxxxXxxxx Xxxx, XxxxxxxxxXxxxxxx, Xxxxxxx XxxxxxxxXxx Xxxx 00000, Xxxxxx X0X 0X0, and our telephone number is or call (000) 000-0000. See We are responsible for the section information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any related free-writing prospectus we prepare or authorize. We have not authorized anyone to give you any other information, and we take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in or incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate as of the date on the front of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies supplement, the accompanying prospectus or incorporated document only, as the case may be. Our business, financial condition, results of materials operations and prospects may have changed since that we file with the SECdate. Any statement contained in this prospectusPROSPECTUS ACORDA THERAPEUTICS, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectusINC.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” into this prospectus supplement and the accompanying prospectus information contained in documents that we file with the SEC, which it. This means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference into this prospectus is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Section Sections 13(a), 13(c), 14, 14 or 15(d) of the Exchange Act prior to the termination of any date that the offering of the securities made by means of this prospectus: • prospectus is completed or terminated, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules, including Current Reports on Form 8-K furnished under Item 2.02 or Item 7.01, including any financial statements or exhibits relating thereto furnished pursuant to Item 9.01): ● our Annual Report on Form 10-K for the fiscal year ended December 31, 20192020, filed with the SEC on March 3February 25, 20202021; • ● our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and 2021, June 30, 20202021 and September 30, 2021, filed with the SEC on May 7, 2020 and August 6, 20202021, August 5, 2021 and November 4, 2021, respectively; • ● our Current Reports on Form 8-K K, filed with the SEC on January 21February 25, 20202021 (excluding such items as deemed furnished in such Form 8-K), January 22March 24, 20202021, February 6March 29, 20202021, April 16May 3, 20202021, May 26, 20202021, June 32, 2021, September 22, 2021, January 31, 2022 (excluding such items as deemed furnished in such Form 8-K), and February 14, 2022, and our Current Reports on Form 8-K/A, filed with the SEC on March 20, 2020, and June August 11, 20202020 and February 9, 2022; • ● our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24March 29, 2020 (but only with respect to information required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2019)2021; • ● the description of our common stock contained in our registration statement Registration Statement on Form 8-A filed with the SEC on July 82, 2015 under Section 12(b) of the Exchange Act2014, including any amendment all amendments and reports filed for purposes of updating such description; ● the description of our Series A Preferred Stock contained in our Registration Statement on Form 8-A/A filed with the SEC on October 19, 2015, including all amendments or report reports filed for the purpose of updating such description, including Exhibit 4.5 to ; and ● the description of our Annual Report Series B Preferred Stock contained in our Registration Statement on Form 108-K for the fiscal year ended December 31, 2019, A filed with the SEC on March 3January 31, 2020; 2022, including all amendments or reports filed for the purpose of updating such description. Any statement incorporated by reference in this prospectus supplement and • filings we make the accompanying prospectus from an earlier dated document that is inconsistent with the SEC pursuant to the Exchange Act a statement contained in this prospectus or in any other document filed after the date of the initial registration statementearlier dated document, of which this prospectus is a part, and but prior to the effectiveness of the registration statement. We will furnish without charge to youdate hereof, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically which also is incorporated by reference into the documents that this prospectus incorporates). Written or oral requests for copies should be directed to Sierra Oncology, Inc., 0000 – 000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxx X0X 0X0, and our telephone number is (000) 000-0000. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a by such statement contained in this prospectusprospectus or in any other document filed after the date of the earlier dated document, any prospectus supplement or any document but prior to the date hereof, which also is incorporated by reference modifies or supersedes such statementinto this prospectus. Any such statement so modified person, including any beneficial owner, to whom this prospectus is delivered may request copies of this prospectus and any of the documents incorporated by reference into this prospectus, without charge, by written or superseded shall notoral request directed to XxxxXxxxx, except 0 Xxxxx Xxxx, Somerset, New Jersey, 08873, telephone: (000) 000-0000, x 133. Except as so modified or supersededexpressly provided above, constitute a part no other information, including none of the information on our website, is incorporated by reference into this prospectus.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can it. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. A Current Report (This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement and any prospectus supplement filed hereafter, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus. Statements in this prospectus regarding the provisions of certain documents filed with, or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectusin, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. We incorporate Copies of all or any part of the registration statement, including the documents incorporated by reference or the documents listed below and any future filings we make with exhibits, may be obtained upon payment of the prescribed rates at the offices of the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made listed above in “Where You Can Find More Information.” The documents we are incorporating by this prospectusreference are: • · our Annual Report on Form 10-K for the fiscal year ended December 31, 20192021, filed with the SEC on March 328, 20202022; • · our Quarterly Reports on Form 10-Q for the quarters fiscal quarter ended March 31, 2020 and 2022, filed on May 10, 2022, for the fiscal quarter ended June 30, 20202022, filed with onAugust 9, 2022, and for the SEC on May 7fiscal quarter ended September 30, 2020 and August 62022, 2020filed onNovember 10, respectively2022; • · our Current Reports on Form 8-K filed with the SEC on January 13, 2022, June 21, 20202022, July 22, 2022, January 22, 2020, February 6, 2020, April 16, 2020, May 26, 2020, June 3, 20202023, and June 11January 20, 20202023; • our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2020 (but only with respect to information required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2019); • and · the description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act, incorporated by reference to our common stock contained in our registration statement Registration Statement on Form 8-8- A filed with the SEC on July 8November 12, 2015 under Section 12(b2021. In addition, all documents that we file pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; and • filings we make with the SEC pursuant subsequent to the Exchange Act after the date filing of the initial registration statement, of which this prospectus is a part, Registration Statement and prior to the effectiveness filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the registration date of filing of such documents, except as to any document or portion of any document that is deemed furnished and not filed. Pursuant to Rule 412 under the Securities Act, any statement contained in the documents incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified, superseded or replaced for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference in this Registration Statement modifies, supersedes or replaces such statement. Any such statement so modified, superseded or replaced shall not be deemed, except as so modified, superseded or replaced, to constitute a part of this Registration Statement. We will furnish provide, without charge charge, to youeach person, on including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral requestrequest of such person, a copy of any or all of such the documents that has been incorporated herein by reference (in this prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates)such documents. Written or oral requests for copies should Requests may be directed to Sierra Oncology, Inc., 0000 – 000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxx X0X 0X0, and our made by telephone number is at (000) 000-0000. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in by sending a documentwritten request to Journey Medical Corporation, all or a portion Attn: Investor Relations, 0000 X Xxx xx Xxxxxxx Xxxx. Xxxxx 000, Xxxxxxxxxx, Xxxxxxx 00000. Our internet address is xxx.xxxxxxx.xxx. S-16 4,900,000 Shares of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.Common Stock PROSPECTUS